| abstract |
The present invention provides a nanobody targeting calreticulin and its application. The complementarity determining region of the amino acid sequence of the nanobody targeting calreticulin is CDR1 as shown in SEQ ID NO:2, such as SEQ ID CDR2 as shown in NO:4, CDR3 as shown in SEQ ID NO:6; or CDR1 as shown in SEQ ID NO:9, CDR2 as shown in SEQ ID NO:11, as shown in SEQ ID NO:13 CDR3. The 204 and 215 nanobodies of the present invention, through the verification of the combination with CRT, have shown that they have a strong binding force with CRT protein, and the affinity with CRT protein is at the nanomolar level, with relatively high affinity; and the Nanobodies have better tissue penetration, can be expressed and purified using the E. coli system, and the production cost is greatly reduced. |